Not available
Quote | Atara Biotherapeutics Inc. (NASDAQ:ATRA)
Last: | $0.61 |
---|---|
Change Percent: | 0.6% |
Open: | $0.6 |
Close: | $0.61 |
High: | $0.6349 |
Low: | $0.585602 |
Volume: | 1,823,190 |
Last Trade Date Time: | 05/17/2024 03:00:00 am |
News | Atara Biotherapeutics Inc. (NASDAQ:ATRA)
2024-05-09 17:26:54 ET More on Atara Biotherapeutics FDA clears Atara to begin Phase 1 study for lupus nephritis drug Baupost Group steps away from Atara, Veritiv; bulks up on Clarivate, Jazz Pharma Seeking Alpha’s Quant Rating on Atara Biotherapeutics ...
Tab-cel ® U.S. BLA on Track for Submission in Q2 2024 Initiation of ATA3219 Lupus Nephritis Study Expected in Q4 2024, with Initial Clinical Data Expected in H1 2025 Initiation of New ATA3219 Cohort Without Lymphodepletion in Severe Systemic Lupus Erythematosus Planned fo...
Message Board Posts | Atara Biotherapeutics Inc. (NASDAQ:ATRA)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $ATRA News Article - Atara Biotherapeutics to Announce First Quarter 2023 Financial Res | whytestocks | investorshangout | 05/01/2023 8:20:47 PM |
whytestocks: $ATRA News Article - Atara Biotherapeutics to Announce Fourth Quarter and Full Year 202 | whytestocks | investorshangout | 02/06/2023 3:35:45 PM |
whytestocks: $ATRA News Article - CHMP Recommends Approval of Atara Biotherapeutics' Ebvallo(TM) (ta | whytestocks | investorshangout | 10/14/2022 12:05:54 PM |
znewcar1: ATRA 25% v6,2M c5.84 f94,4M H5.87 ML2.83 | znewcar1 | investorshangout | 08/12/2022 8:46:00 PM |
znewcar1: ATRA 29% v14,5M c4.69 f93,4M H4.92 ML2.83 gap down | znewcar1 | investorshangout | 08/09/2022 8:10:31 PM |
News, Short Squeeze, Breakout and More Instantly...
Atara Biotherapeutics Inc. Company Name:
ATRA Stock Symbol:
NASDAQ Market:
Atara Biotherapeutics Inc. Website:
Tab-cel ® U.S. BLA on Track for Submission in Q2 2024 Initiation of ATA3219 Lupus Nephritis Study Expected in Q4 2024, with Initial Clinical Data Expected in H1 2025 Initiation of New ATA3219 Cohort Without Lymphodepletion in Severe Systemic Lupus Erythematosus Planned fo...
Tab-cel ® U.S. BLA on Track for Submission in Q2 2024 Following Positive Pre-BLA Meeting Allogeneic CAR T Pipeline Expands Into Autoimmune Disease With Plans to Initiate an ATA3219 Lupus Nephritis Study in H2 2024, and Initial Clinical Data Expected H1 2025 AT...